知镜 Cognispect · 医学文献与研究工作台

Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.

Zhong SS, Yu Y, Zhong XH, Xie J, Liu MS.
Drug design, development and therapy · 2026-11-04 · PMID 43001154

文献摘要

Hepatocellular carcinoma (HCC) usually develops in a chronically inflamed, fibrotic, and immunologically tolerogenic liver. This context shapes antitumor immunity, competing liver-related mortality, and access to subsequent therapy. As hepatic reserve, disease etiology, and regional treatment patterns differ substantially across patients and healthcare settings, immunotherapy outcomes are correspondingly heterogeneous. Immune-checkpoint inhibitors have transformed systemic treatment through combinations that target complementary immune, vascular, or signaling barriers. Atezolizumab plus bevacizumab established combined PD-L1 and VEGF inhibition, whereas STRIDE and nivolumab plus ipilimumab validated dual-checkpoint blockade with distinct CTLA-4 exposure. Camrelizumab plus rivoceranib confirmed the activity of PD-1 and VEGFR2 inhibition. Negative or mixed Phase III trials nevertheless show that biological rationale and higher response rates do not ensure a survival benefit. Immunotherapy is moving into intermediate-stage and perioperative disease, but the updated IMbrave050 findings illustrate the difficulty of achieving durable adjuvant benefit. No validated predictive biomarker currently guides selection among approved regimens. Furthermore, since most HCCs arise in a chronically diseased liver, hepatic reserve and liver-related competing mortality are central determinants of treatment eligibility, tolerance, and survival. This narrative review (literature search through May 31, 2026) is distinguished by its focus on hepatic reserve as a determinant of treatment selection and outcome, and by framing treatment failure as a composite of tumor-driven resistance and liver-related competing mortality. We synthesize evidence on clinical development, resistance, biomarkers, emerging therapies, underrepresented populations, hepatic reserve, and rational subsequent therapy. Further progress will depend on matching defined failure mechanisms to appropriate interventions while preserving hepatic reserve.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。